Novolin 70/30

   
Google
 
Web NewDrugInformation.com

Novolin 70/30


Drug - Novolin 70/30
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Insulin Recombinant Purified Human; Insulin Susp Isophane Semisynthetic Purified Human
Multiple ingredients are in alphabetical order.

Strength - 30 UNITS/ML;70 UNITS/ML
The potency of the active ingredient(s), Insulin Recombinant Purified Human; Insulin Susp Isophane Semisynthetic Purified Human. May repeat for multiple part products.

Applicant - NOVO NORDISK INC
The firm name holding legal responsibility for Novolin 70/30. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 019441
The FDA assigned number to Novolin 70/30. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Novolin 70/30. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jul 11, 1986
The date Novolin 70/30 was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Novolin 70/30. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Novolin 70/30 is in. Format is RX, OTC, DISCN.

Applicant Full Name - Novo Nordisk Inc
The full name of the firm holding legal responsibility for the new application of Novolin 70/30.

Novolin 70/30